Skip to content

Medline

US · MDLN #667 by market cap Listed 2025
37.04 -0.80 -2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 37.74 -0.26%
After-hours 37.04 0.00%
43.1931.6437.042026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MDLN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +13.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 4.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall B-

The radar needs all six factors. Available grades are shown below.

Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 57.5x Better than 8%
Forward P/E 22.1x Better than 30%
Price / Sales 1.1x Better than 76%
P/E vs own 5-yr range 69th pctl Better than 39%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability B-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 26.4% Better than 27%
Operating margin 7.8% Better than 44%
Net margin 4.1% Better than 40%
Return on equity 21.3% Better than 80%
Return on invested capital 9.5% Better than 66%
Momentum B+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 8.1% Better than 88%
6-month return 0.1% Better than 56%
Distance below 52-week high 27.2% Better than 47%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.3x Better than 82%
Debt to assets 32.8% Better than 37%
Interest coverage 2.5x Better than 41%
Free cash flow / net income 111.9% Better than 46%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 28.6% Better than 47%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.16%
1M +4.46%
3M +13.69%
6M +2.18%
YTD -11.81%

Key statistics

Price & volume

Prev close
37.84
Open
37.65
Day range
36.94 - 38.37
Avg price
37.32
Volume
9.33M
Turnover
348.25M
Amplitude
3.78%
52-week range
31.37 - 50.88

Valuation

P/E
25.96
P/E (TTM)
57.52
P/B
2.76
EPS
1.43
Net profit
1.25B
Net assets
11.80B

Share structure

Market cap
32.55B
Float cap
14.15B
Shares out
878.66M
Float shares
382.04M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2025-12-17
52-week range 29% of range
31.37 50.88

27.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-37.07M net over the window

Short interest

Shares short
37.84M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Medline (MDLN)?

Medline last traded at 37.04. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Medline's market cap?

About 32.55B.

What is the P/E ratio of Medline?

The trailing twelve-month P/E is 57.52, above its own 5-year average of 40.81 — toward the top of its historical range (69.01% percentile). See the Valuation tab for the full history.

Does Medline pay a dividend?

Medline does not currently pay a regular dividend.

Is Medline a buy according to analysts?

The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 47.64, which implies 28.6% upside from the current price. This is not investment advice.

What is Medline's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Medline a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Medline discussion 0 comments

Add a comment